Enveric Biosciences Inc

Company Profile

Enveric Biosciences Inc had its IPO on 2015-06-24 under the ticker symbol ENVB.

The company operates in the Healthcare sector and Biotechnology industry. Enveric Biosciences Inc has a staff strength of 25 employees.

Stock update

Shares of Enveric Biosciences Inc opened at $2.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.31 - $2.51, and closed at $2.38.

This is a -0.42% slip from the previous day's closing price.

A total volume of 39,183 shares were traded at the close of the day’s session.

In the last one week, shares of Enveric Biosciences Inc have increased by +12%.

Enveric Biosciences Inc's Key Ratios

Enveric Biosciences Inc has a market cap of $9.06 million, indicating a price to book ratio of 0.222 and a price to sales ratio of 0.0831.

In the last 12-months Enveric Biosciences Inc’s revenue was $35.41 million with a gross profit of $8.15 million and an EBITDA of $-19681146. The EBITDA ratio measures Enveric Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Enveric Biosciences Inc’s operating margin was 0% while its return on assets stood at -52.12% with a return of equity of -103.89%.

In Q1, Enveric Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 7.3%.

Enveric Biosciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-10.67 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enveric Biosciences Inc’s profitability.

Enveric Biosciences Inc stock is trading at a EV to sales ratio of 1.7579 and a EV to EBITDA ratio of 0.2664. Its price to sales ratio in the trailing 12-months stood at 0.0831.

Enveric Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$15.85 million

Total Liabilities

$4.44 million

Operating Cash Flow

$0

Capital Expenditure

$5169

Dividend Payout Ratio

0%

Enveric Biosciences Inc ended 2025 with $15.85 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.85 million while shareholder equity stood at $10.41 million.

Enveric Biosciences Inc ended 2025 with $0 in deferred long-term liabilities, $4.44 million in other current liabilities, 20782.00 in common stock, $-83885313.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.56 million and cash and short-term investments were $12.56 million. The company’s total short-term debt was $37,044 while long-term debt stood at $0.

Enveric Biosciences Inc’s total current assets stands at $14.84 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.79 million and inventory worth $0.

In 2025, Enveric Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $5169.

Comparatively, Enveric Biosciences Inc paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$2.38

52-Week High

$18.5

52-Week Low

$1.3

Analyst Target Price

$7

Enveric Biosciences Inc stock is currently trading at $2.38 per share. It touched a 52-week high of $18.5 and a 52-week low of $18.5. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $2.57 and 200-day moving average was $2.52 The short ratio stood at 0.6 indicating a short percent outstanding of 0%.

Around 1259.3% of the company’s stock are held by insiders while 842.2% are held by institutions.